Centene Corp (CNC) FinancialsCNCCentene Corp

Centene Corp (CNC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medicaid, accounting for 59.7% of total sales, equivalent to $31.97B. Other significant revenue streams include Medicare and Commercial. Understanding this composition is critical for investors evaluating how CNC navigates market cycles within the Managed Healthcare industry.

Evaluating the bottom line, Centene Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 2.33%, while the net margin is 2.03%. These profitability ratios, combined with a Return on Equity (ROE) of -20.41%, provide a clear picture of how effectively CNC converts its operational activities into shareholder value.

In the context of the broader market, CNC competes directly with industry leaders such as HUM and OSCR. With a market capitalization of $33.11B, it holds a significant position in the sector. When comparing efficiency, CNC's gross margin of N/A stands against HUM's N/A and OSCR's N/A. Such benchmarking helps identify whether Centene Corp is trading at a premium or discount relative to its financial performance.

Centene has shown a significant recovery in net income, reporting $1.54 billion in Q1 2026 and $1.09 billion in Q2 2026, after a challenging 2025. The company also has a forward EV/EBITDA of 2.85, indicating strong potential for future earnings relative to its enterprise value.